Cariprazine
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethyl-urea | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Non-regulated |
| Identifiers | |
| CAS number | 839712-12-8 |
| ATC code | None |
| ChemSpider | 25999972 |
| UNII | F6RJL8B278 |
| Chemical data | |
| Formula | C21H32Cl2N4O |
| Mol. mass | 427.411 g/mol |
| SMILES | eMolecules & PubChem |
|
Cariprazine (RGH-188) is an antipsychotic drug by Gedeon Richter. It acts as a D2 and D3 receptor antagonist, with high selectivity towards the D3 receptor.[1] Phase III studies are ongoing for schizophrenia and mania in bipolar disorder I, as are Phase II studies for bipolar depression[2]. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder [3]
Forest Laboratories obtained a license on development and exclusive commercial rights in the US in 2004.
[edit] References
- ^ Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K et al (2010). "Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile". The Journal of pharmacology and experimental therapeutics 333 (1): 328–340. PMID 20093397.
- ^ Gründer G (2010). "Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression". Current opinion in investigational drugs 11 (7): 823–832. PMID 20571978.
- ^ Clinical trial : Safety and Efficacy of Caripazine As Adjunctive Therapy In Major Depressive Disorder
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
